# Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta [T cell](https://www.edgepedia.org/t-cell) therapies for autoimmune diseases and cancer.[1](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000029/acet-2025_annual_report.pdf) It was incorporated in Delaware in November 2014, spent its first six years as a private Menlo Park-based startup, and became a public company through an all-stock merger with resTORbio completed on September 15, 2020; it trades on Nasdaq under the ticker ACET and has its principal executive offices in Boston, Massachusetts, with offices in [Redwood City, California](https://www.edgepedia.org/redwood-city-california).[2](https://investor.adicetbio.com/static-files/4486da9c-f386-4a18-ac37-9d46b12f808c)
| Key facts | |
|---|---|
| Founded | November 2014, Delaware incorporation[2](https://investor.adicetbio.com/static-files/4486da9c-f386-4a18-ac37-9d46b12f808c) |
| Sector | Allogeneic gamma delta T cell immunotherapy for autoimmune disease and cancer[1](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000029/acet-2025_annual_report.pdf) |
| Founder | Aya Jakobovits, former President and founding CEO of Kite Pharma[3](https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex994.htm) |
| Current CEO | Chen Schor (President and CEO since the 2020 merger)[4](https://www.sec.gov/Archives/edgar/data/1720580/000119312520245865/d50689dex991.htm) |
| Private capital raised | Approximately $124 million per the 2020 proxy[3](https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex994.htm) |
| Public listing | Nasdaq: ACET, since September 16, 2020, via merger with resTORbio[4](https://www.sec.gov/Archives/edgar/data/1720580/000119312520245865/d50689dex991.htm) |
| Cash position | $137.6 million as of March 31, 2026; runway into the second half of 2027[5](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/acet-ex99_1.htm) |
| Status | Operating public clinical-stage company as of March 2026[6](https://www.businesswire.com/news/home/20260312316837/en/Adicet-Bio-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Highlights-Recent-Company-Progress) |
## History and founding
Former Adicet was incorporated in Delaware in November 2014.[2](https://investor.adicetbio.com/static-files/4486da9c-f386-4a18-ac37-9d46b12f808c) Its founder and first President and CEO, Aya Jakobovits, had previously been the President and founding CEO of Kite Pharma.[3](https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex994.htm)
Two early transactions shaped the platform. In 2016, Adicet acquired Applied Immune Technologies Ltd., a Haifa-based company founded in 2006 that became its wholly owned Israeli subsidiary, Adicet Bio Israel Ltd.; after the company consolidated operations in the United States in 2019, the Israeli operation's activities were substantially reduced.[2](https://investor.adicetbio.com/static-files/4486da9c-f386-4a18-ac37-9d46b12f808c) On July 29, 2016, Adicet entered a license and collaboration agreement with [Regeneron Pharmaceuticals](https://www.edgepedia.org/regeneron-pharmaceuticals), amended in April 2019 in connection with Regeneron's investment.[2](https://investor.adicetbio.com/static-files/4486da9c-f386-4a18-ac37-9d46b12f808c)
The company went public through a reverse merger rather than an IPO. On September 15, 2020, Former Adicet completed an all-stock merger with resTORbio, Inc. (previously Nasdaq: TORC); the combined company took the Adicet Bio name and began trading as ACET on September 16, 2020.[4](https://www.sec.gov/Archives/edgar/data/1720580/000119312520245865/d50689dex991.htm) resTORbio effected a 7:1 reverse stock split at closing, and after the merger Adicet had approximately 19,589,828 shares outstanding, with prior Adicet equityholders owning approximately 75% of the combined company on a fully diluted basis and prior resTORbio holders approximately 25%.[4](https://www.sec.gov/Archives/edgar/data/1720580/000119312520245865/d50689dex991.htm) The combined company is led by Chen Schor as President and CEO, with a board including Carl Gordon, Erez Chimovits, Aya Jakobovits, and Yair Schindel from Adicet's prior board, and offices in Menlo Park and Boston.[4](https://www.sec.gov/Archives/edgar/data/1720580/000119312520245865/d50689dex991.htm)
## Technology and pipeline
Adicet's products are built on gamma delta T cells, a T cell subset that, unlike alpha beta T cells, performs its tumor-killing function in an MHC-independent (kills cells without the usual immune matching system) manner.[7](https://www.adicetbio.com/science/) According to the company, this allows cells from unrelated donors to be used allogeneically without causing graft-versus-host disease (GvHD); the cells also naturally home to tissues.[7](https://www.adicetbio.com/science/) The company's own annual report describes its "off-the-shelf" manufacturing as designed to allow product from unrelated donors to be stored and sold on demand without inducing a graft-versus-host immune response, in contrast to alpha beta T cell products that must be manufactured per patient or heavily gene-edited.[1](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000029/acet-2025_annual_report.pdf) A manufacturing constraint is that gamma delta T cells represent only 1-5% of peripheral blood mononuclear cells, so expansion processes are required.[7](https://www.adicetbio.com/science/)
The lead candidate is prulacabtagene leucel (prula-cel, formerly ADI-001), described by the company as a first-in-class allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor (CAR) targeting CD20, developed for the potential treatment of autoimmune diseases.[1](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000029/acet-2025_annual_report.pdf) Its Phase 1 program spans lupus nephritis, systemic lupus erythematosus (SLE), systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, and ANCA-associated disease.[8](https://www.adicetbio.com/pipeline/)
The second clinical-stage candidate, ADI-212, targets PSMA for solid tumors and integrates membrane-tethered IL-12 armoring with CRISPR/Cas9-mediated disruption of [MED12](https://www.edgepedia.org/med12) (subunit 12 of the mediator complex) to enhance potency.[1](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000029/acet-2025_annual_report.pdf) A third candidate, ADI-270, an anti-CD70 armored therapy for metastatic/advanced clear cell renal cell carcinoma, was discontinued in July 2025.[9](https://investor.adicetbio.com/static-files/152bc045-50ea-4b52-bc2a-22978fe0822d)
Adicet has also described a proprietary TCRL platform (T cell receptor-like), which generates CARs recognizing intracellular tumor antigens, addressing the scarcity of tumor-specific surface antigens on solid tumors.[3](https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex994.htm)
## Funding, by the numbers
The 2020 merger proxy statement states Adicet had received investments valued at an aggregate of approximately $124 million from investors including aMoon, Consensus Business Group, DSC Investment, Handok, Johnson & Johnson Innovation-JJDC, KB Investment, OCI Enterprises, Novartis Venture Fund, OrbiMed, Pontifax, Regeneron Pharmaceuticals, Samsung Venture Investment, and SBI JI Innovation Fund.[3](https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex994.htm) Within that total, Regeneron exercised an investment right and purchased approximately $10.0 million of Series B preferred stock in a private placement in July 2019.[3](https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex994.htm)
After the 2020 merger, the company's capital has been tracked through quarterly reports. Cash, cash equivalents, and short-term investments were $158.5 million as of December 31, 2025, and $137.6 million as of March 31, 2026; the company expects that balance to fund operating expenses into the second half of 2027.[5](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/acet-ex99_1.htm)
## Business, clinical progress and traction
Adicet's clinical calendar has concentrated on a mid-2026 data readout. In October 2025 the company reported Phase 1 data for prula-cel in lupus nephritis and SLE patients.[1](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000029/acet-2025_annual_report.pdf) On May 13, 2026, CEO Chen Schor said the company was approaching "a key inflection point" and would report Phase 1 data for prula-cel in mid-2026, including data from at least 20 LN and SLE patients with a minimum of six months of follow-up; he also described an ongoing preclinical in vivo CAR-T platform targeting hematologic malignancies.[5](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/acet-ex99_1.htm) In its fourth quarter and full year 2025 results (March 12, 2026), the company said it expected to complete enrollment in prula-cel Phase 1 indications including SLE and systemic sclerosis in the first half of 2026, and to submit a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in the third quarter of 2026.[10](https://adicetbio.gcs-web.com/news-releases/news-release-details/adicet-bio-reports-fourth-quarter-and-full-year-2025-financial)
Geographically, the company established Adicet (Shanghai) Biotechnology Co., Ltd., a wholly owned subsidiary founded in May 2024, to conduct R&D activities in China through contractual agreements.[1](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000029/acet-2025_annual_report.pdf) • [2](https://investor.adicetbio.com/static-files/4486da9c-f386-4a18-ac37-9d46b12f808c)
## Competitive position
Adicet's 2025 annual report names its allogeneic T-cell competitors as Allogene Therapeutics, Caribou Biosciences, Century Therapeutics, Cellectis, CRISPR Therapeutics, Fate Therapeutics, Precision Biosciences, Immatics, TC BioPharm, and IN8bio, and its autologous competitors as Bristol-Myers Squibb, Gilead, Johnson & Johnson, Novartis, Autolus, Adaptimmune, Iovance, Mustang Bio, and [Legend Biotech](https://www.edgepedia.org/legend-biotech).[1](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000029/acet-2025_annual_report.pdf) Adicet's differentiation claim rests on the gamma delta subset's MHC-independent killing, which the company says permits allogeneic use without GvHD risk, unlike alpha beta T cell approaches.[7](https://www.adicetbio.com/science/)
## Recent developments
The company's focus has shifted toward autoimmune indications, where prula-cel is now the lead program. In July 2025, the board approved a reduction of approximately 30% of the workforce in connection with strategic pipeline prioritization, with expected one-time personnel-related restructuring charges of approximately $2.3 million, substantially complete by the end of the third quarter of 2025; the company discontinued ADI-270 and said the cuts were expected to extend its cash runway into the fourth quarter of 2026.[9](https://investor.adicetbio.com/static-files/152bc045-50ea-4b52-bc2a-22978fe0822d) Subsequent reporting put cash at $137.6 million as of March 31, 2026 with runway into the second half of 2027.[5](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/acet-ex99_1.htm) The company has also announced a reverse stock split.[11](http://www.adicet.bio/)
## References
1. Adicet Bio 2025 Annual Report, SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1720580/000172058026000029/acet-2025_annual_report.pdf
2. Adicet Bio 10-K, Organization and Nature of the Business. https://investor.adicetbio.com/static-files/4486da9c-f386-4a18-ac37-9d46b12f808c
3. Adicet Bio proxy statement/prospectus (EX-99.4, 2020), SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex994.htm
4. Adicet Bio/resTORbio merger completion press release (EX-99.1, September 15, 2020), SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1720580/000119312520245865/d50689dex991.htm
5. Adicet Bio Q1 2026 financial results press release (EX-99.1, May 13, 2026), SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/acet-ex99_1.htm
6. Business Wire: Adicet Bio Q4/FY2025 Financial Results (March 12, 2026). https://www.businesswire.com/news/home/20260312316837/en/Adicet-Bio-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Highlights-Recent-Company-Progress
7. Gamma Delta (γδ) T cells | Adicet Bio (company website). https://www.adicetbio.com/science/
8. Pipeline | Adicet Bio (company website). https://www.adicetbio.com/pipeline/
9. Adicet Bio Form 8-K (July 2025), restructuring and pipeline prioritization. https://investor.adicetbio.com/static-files/152bc045-50ea-4b52-bc2a-22978fe0822d
10. Adicet Bio Q4 and Full Year 2025 Financial Results (company press release, March 12, 2026). https://adicetbio.gcs-web.com/news-releases/news-release-details/adicet-bio-reports-fourth-quarter-and-full-year-2025-financial
11. Adicet Bio company website. http://www.adicet.bio/
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Cell and gene therapy developers › Cell therapy developers*
*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026 · Edited: Oct 11, 2026; Oct 15, 2026 · Last review: Sep 30, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license